Recent advances in the antiphospholipid antibody syndrome

Current Opinion in Hematology

Volumn 21, Issue 5, 2014, Pages 371-379

  Chaturvedi, Shruti ^a   McCrae, Keith R ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

antiphospholipid; lupus anticoagulant; thrombosis; 2 glycoprotein I

Indexed keywords

COMPLEMENT INHIBITOR; DEFIBROTIDE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RITUXIMAB; COMPLEMENT;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL ACTIVATION; COMPLEMENT ACTIVATION; ENDOTHELIUM CELL; HUMAN; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOSIS; IMMUNOLOGY;

ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT SYSTEM PROTEINS; HUMANS; RISK ASSESSMENT;

EID: 84906074151     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000067     Document Type: Article

References (72)

1. Miyakis S, Lockshin MD, Atsumi D, et al. International consensus statement on an update of the preliminary classification criteria or antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306
2. Cervera R, Piette J, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46:1019-1027
3. Asherson RA, Cervera R, Piette J, et al. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12:530-534
4. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis 2014. [Epub ahead of print]
5. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74:1185-1190
6. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110:1178-1183
7. Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood 2010; 115:870-878
8. Banzato A, Pozzi N, Frasson R, et al. Antibodies to domain I of beta(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res 2011; 128:583-586
9. Sciascia S, Sanna G, Murru V, et al. Antiprothrombin (aPT) and antiphosphatidylserine/ prothrombin (aPS/PT)antibodies and the risk of thrombosis in the antiphospholipid syndrome. Thromb Haemost 2014; 111:354-364
10. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: B 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4124
11. Arad A, Proulle V, Furie RA, et al. b(2)-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011; 117:3453-3459
12. Redecha P, Franzke CW, Ruf W, et al. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008; 118:3453-3461
13. Rand JH, Wu XX. Antibody-mediated disruption of the annexin-V antithrombotic shield: A new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999; 82:649-655
14. Hunt JE, Simpson RJ, Chesterman CN, et al. Identification of a region of beta- 2-glycoprotein I critical for lipid binding and anticardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90:2141-2145
15. Agar C, Van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116:1336-1343
16. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol 2011; 7:330-339
17. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 11:1033-1044
18. Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12:53-57
19. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211-2219
20. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/antibeta2 glycoprotein I antibodies. Blood 2005; 105: 1964-1969
21. Nojima J, Masuda Y, Iwatani Y, et al. Tissue factor expression on monocytes induced by antiphospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. Biochem Biophys Res Commun 2008; 365:195-200
22. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70:667-671
23. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. 'Anticardiolipin' autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154:954-960
24. Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000; 84:742-746
25. Allen KL, Fonseca FV, Betapudi V, et al. A novel pathway for human endothelial cell activation by antiphospholipid/antib2 glycoprotein I antibodies. Blood 2012; 119:884-893
26. Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101:3495-3500
27. Zhou H, Sheng L, Wang H, et al. Antib2GPI/b2GPI stimulates activation of THP-1 cells through TLR4/MD-2/MyD88 and NF-kB signaling pathways. Thromb Res 2013; 132:742-749
28. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogenactivated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007; 5:1828-1834
29. Ramesh S, Morrell CN, Tarango C, et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via b2GPI and apoER2. J Clin Invest 2011; 121:120-131
30. Alard JE, Gaillard F, Daridon C, et al. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol 2010; 185:1550-1557
31. Sorice M, Longo A, Capozzi A, et al. Antibeta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56:2687-2697
32. López-Pedrera C, Buendía P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kB/Rel proteins via the p38 mitogen-Activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54:301-311
33. Urbanus RT, Pennings MT, Derksen RH, De Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ib alpha and apolipoprotein E receptor 20 . J Thromb Haemost 2008; 6:1405-1412
34. Shi T, Giannakopoulos B, Yan X, et al. Antibeta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54:2558-2567
35. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76:101-107
36. Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104:2783-2790
37. Chamley LW, McKay EJ, Pattison NS. Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies: A mechanism for thrombosis. Thromb Res 1993; 71:103-111
38. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: A newin vitro manifestation of lupus anticoagulant. Blood 1989; 74:2426-2432
39. Vega-Ostertag M, Liu X, Kwan-Ki H, et al. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 2006; 135:214-219
40. Hwang KK, Grossman JM, Visvanathan S, et al. Identification of antithrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167:7192-7198
41. Giannakopoulos B, Gao L, Qi M, et al. Factor XI is a substrate for oxidoreductases: Enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis. J Autoimmun 2012; 39:121-129
42. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: Evidence for a novel effect for an old antimalarial drug. Blood 2010; 115:2292-2299
43. Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96:4380-4384
44. Chen PP, Yang CD, Ede K, et al. Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis. Lupus 2008; 17:916-921
45. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta 2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106:2340-2346
46. Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor crosstalk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177:4794-4802
47. Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003; 12:535-538
48. Carrera-Marín A, Romay-Penabad Z, Papalardo E, et al. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus 2012; 21:1497-1505
49. Breen KA, Seed P, Parmar K, et al. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012; 107:423-429
50. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459-465
51. Uthman IW, Gharavi AE. Viral infection and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31:256-263
52. Van Os GM, Meijers JC, Agar C, et al. Induction of anti-b2 glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost 2011; 9:2447-2456
53. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: The role of oxidative posttranslational modification of beta 2 glycoprotein I. J Thromb Haemost 2011; 9:275-282
54. Rauch J, DieudéM, Subang R, Levine JS. The dual role of innate immunity in the antiphospholipid syndrome. Lupus 2010; 19:347-353
55. Aguilar-Valenzuela R, Nickerson K, Romay-Penabad Z, et al. Involvement of TLR7 and TLR9 in the production of antiphospholipid antibodies. Arthritis Rheum 2011; 63:s281
56. Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol 2013; 40:30-33
57. Cervera R, Khamastha MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5 year period: A multicenter prospective study of 1000 patients. Ann Rheum Dis 2009; 68:1428-1432
58. Tripodi A, Chantarangkul V, Clerici M, et al. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Br J Haematol 2001; 115:672-678
59. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: Task Force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13:685-696
60. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004; 2:1558-1563
61. Redecha P, Franzke CW, Ruf W, et al. Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008; 118:3453-3461
62. Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2013; 73(6):1176-1180
63. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011; 13:77-80
64. Wu XX, Guller S, Rand JH. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol 2011; 205:e7-e14
65. Schmidt-Tanguy A, Voswinkel J, Henrion D, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 2013; 11:1927-1929
66. Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10:664-668
67. Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2012; 12:1085-1090
68. Erkan D, Vega J, RamónG, et al. A pilot open-label phase II trial of rituximab for noncriteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013; 65:464-471
69. Akkerman A, Huang W, Wang X, et al. CTLA4Ig prevents initiation but not evolution of antiphospholipid syndrome in NZW/BXSB mice. Autoimmunity 2004; 37:445-451
70. Kahn P, Ramanujman M, Bethunaickan R, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008; 58:2824-2834
71. Montiel-Manzano G, Romay-Penabad Z, Papalardo De Martinez E, et al. In vivo effects of an inhibitor of nuclear factor kappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci 2007; 1108: 540-553
72. Xie H, Zhou H, Wang H, et al. Antib(2)GPI/b(2)GPI induced TF and TNF-A expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol 2013; 53:246-254.